The SEDAN score calculator assesses the risk of symptomatic intracranial hemorrhage (ICH) by evaluating five clinical factors related to a patient's admission characteristics. Each factor is assigned a score based on predefined criteria, and the sum of these scores provides an overall risk assessment for ICH.

The inputs and corresponding score assignments are as follows:

1. Blood Glucose Level on Admission:
   - <= 8 mmol/L [< 145 mg/dL]: Score = 0
   - 8.1-12 mmol/L [145-216 mg/dL]: Score = 1
   - > 12 mmol/L [> 216 mg/dL]: Score = 2

2. Early Infarct Signs on Admission CT:
   - Yes: Score = 1
   - No: Score = 0

3. Dense or Hyperdense Cerebral Artery Sign on Admission CT:
   - Yes: Score = 1
   - No: Score = 0

4. Age > 75 Years:
   - Yes: Score = 1
   - No: Score = 0

5. NIH Stroke Scale >= 10:
   - Yes: Score = 1
   - No: Score = 0

Each input is scored independently, and the total score is calculated by summing the individual scores. The total SEDAN score can range from 0 to 6. Based on this total score, the risk of symptomatic ICH is interpreted as follows:

- Score 0: Risk of symptomatic ICH is 1%
- Score 1: Risk of symptomatic ICH is 3.5%
- Score 2: Risk of symptomatic ICH is 5.1%
- Score 3: Risk of symptomatic ICH is 9.2%
- Score 4: Risk of symptomatic ICH is 16.9%
- Score 5: Risk of symptomatic ICH is 27.8%

The SEDAN score is a clinical calculator used to predict the risk of symptomatic intracranial hemorrhage (sICH) after thrombolytic therapy in patients with acute ischemic stroke. The acronym SEDAN stands for "Sugar (blood glucose), Early Infarct Signs, Dense cerebral artery sign, Age, and NIHSS score". 

This scoring system applies to patients who have suffered an acute ischemic stroke and are being considered for thrombolytic therapy. The SEDAN score helps clinicians to stratify the risk of sICH, a serious complication of thrombolytic therapy, and thus aids in making informed decisions about the use of this treatment.

The SEDAN score is not applicable to patients with hemorrhagic stroke, those who are not candidates for thrombolytic therapy, or those with contraindications to this treatment. It should also be used with caution in patients with severe renal or hepatic impairment, as these conditions can affect blood glucose levels and the metabolism of thrombolytic agents.

SEDAN score for symptomatic intracranial hemorrhage